Journal of Rehabilitation Medicine 51-5 | Page 14

N. Firth et al. 2014; 9: 321–327. 62. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002; 8: 495–505. 63. Grade C, Redford B, Chrostowski J, Toussaint L, Blackwell B. Methylphenidate in early poststroke recovery: a double- blind, placebo-controlled study. Arch Phys Med Rehabil 1998; 79: 1047–1050. 64. Schaebitz WR, Laage R, Vogt G, Koch W, Kollmar R, Schwab S, et al. AXIS A Trial of intravenous granulocyte colony- stimulating factor in acute ischemic stroke. Stroke 2010; 41: 2545–2551. 65. Kwakkel G, Lannin NA, Borschmann K, English C, Ali M, Churilov L, et al. Standardized measurement of sensorimo- tor recovery in stroke trials: consensus-based core recom- mendations from the Stroke Recovery and Rehabilitation Roundtable. Int J Stroke 2017; 12: 451–461. 66. Walker MF, Hoffmann TC, Brady MC, Dean CM, Eng JJ, Farrin AJ, et al. Improving the development, monitoring and reporting of stroke rehabilitation research: consensus- based core recommendations from the Stroke Recovery and Rehabilitation Roundtable. Int J Stroke 2017; 12: 472–479. 67. Micromedex® 2.0. Truven Health Analytics. 2017 [cited 2017 Mar 30]. Available from: http://www.micromedexso- lutions.com.elibrary.jcu.edu.au/. 68. Mead G, Hackett ML, Lundström E, Murray V, Hankey GJ, Dennis M. The FOCUS, AFFINITY and EFFECTS trials stu- dying the effect(s) of fluoxetine in patients with a recent stroke: a study protocol for three multicentre randomised 330 www.medicaljournals.se/jrm controlled trials. Trials 2015; 16: 369. 69. Dennis M, Mead G, Forbes J, Graham C, Hackett M, Han- key GJ, et al. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet 2019; 393: 265–274. 70. Anon C. ICH S7A: safety pharmacology studies for human pharmaceuticals. London: The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use CPMP/ICH/539/00; 2000, p. 1–9. 71. Névéol A, Doğan RI, Lu Z. Author keywords in biomedical journal articles. AMIA Annual Symposium proceedings AMIA Symposium 2010; 2010: 537–541. 72. Corbett D, Carmichael ST, Murphy TH, Jones TA, Schwab ME, Jolkkonen J, et al. Enhancing the alignment of the preclinical and clinical stroke recovery research pipeline: consensus-based core recommendations from the Stroke Recovery and Rehabilitation Roundtable translational wor- king group. Int J Stroke 2017; 12: 462–471. 73. van Vliet P, Hunter SM, Donaldson C, Pomeroy V. Using the TIDieR Checklist to standardize the description of a functional strength training intervention for the upper limb after stroke. J Neurol Phys Ther 2016; 40: 203–208. 74. Schulz KF, Altman DG, Moher D. CONSORT 2010 State- ment: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340: c332. 75. Australian Medicines Handbook 2017. Australian Medicines Handbook Pty Ltd; 2017. Available from: https://amhon- line.amh.net.au/. 76. eTG complete 2018. West Melbourne, VIC, Australia: Th- erapeutic Guidelines Ltd; 2018.